BUSINESS SEGMENT INFORMATION (Tables)

6 Months Ended

Jun. 30, 2014

Segment Reporting [Abstract]

Revenues by Products [Table Text Block]

Product revenues were as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions	2014		2013		2014		2013
Virology
Baraclude (entecavir)	$	369	$	371	$	775	$	737
Reyataz (atazanavir sulfate)	362		431		706		792
Sustiva (efavirenz) Franchise(a)	361		411		680		798
Oncology
Erbitux* (cetuximab)	186		171		355		333
Sprycel (dasatinib)	368		312		710		599
Yervoy (ipilimumab)	321		233		592		462
Neuroscience
Abilify* (aripiprazole)(b)	555		563		1,095		1,085
Immunoscience
Orencia (abatacept)	402		352		765		672
Cardiovascular
Eliquis (apixaban)	171		12		277		34
Diabetes Alliance(c)	27		438		206		796
Mature Products and All Other(d)	767		754		1,539		1,571
Total Revenues	$	3,889	$	4,048	$	7,700	$	7,879

*	Indicates brand names of products which are trademarks not owned or wholly owned by BMS. Specific trademark ownership information can be found at the end of this quarterly report on Form 10-Q.
(a)	Includes alliance and other revenue of $313 million and $346 million for three months ended June 30, 2014 and 2013, respectively, and $585 million and $670 million for the six months ended June 30, 2014 and 2013, respectively.
(b)	Includes alliance and other revenue of $499 million and $454 million for three months ended June 30, 2014 and 2013, respectively, and $940 million and $849 million for the six months ended June 30, 2014 and 2013, respectively.
(c)	Includes Bydureon* (exenatide extended-release for injectable suspension), Byetta* (exenatide), Farxiga*/Xigduo* (dapagliflozin/dapagliflozin and metformin hydrochloride), Onglyza*/Kombiglyze* (saxagliptin/saxagliptin and metformin), Myalept* (metreleptin) and Symlin* (pramlintide acetate).
(d)	Includes Plavix* (clopidogrel bisulfate) revenues of $45 million and $44 million for the three months ended June 30, 2014 and 2013, respectively, and $93 million and $135 million for the six months ended June 30, 2014 and 2013, respectively. Additionally, includes Avapro*/Avalide* (irbesartan/irbesartan-hydrochlorothiazide) revenues of $59 million and $56 million for the three months ended June 30, 2014 and 2013, respectively, and $115 million and $102 million for the six months ended June 30, 2014 and 2013, respectively.